Results 171 to 180 of about 50,819 (268)

Autoimmunity: Molecular Mechanisms, Biomarkers, and Therapeutic Opportunities

open access: yesMedComm, Volume 7, Issue 9, September 2026.
Major types of immunometabolism, epigenetics, posttranscriptional regulation, and functional reprogramming involved in autoimmune diseases. The roles of immunometabolism, epigenetics, posttranscriptional regulation, and functional reprogramming in autoimmune diseases have been a major research focus in recent years.
Jialong Kuang   +10 more
wiley   +1 more source

Possible involvement of viral infection in the pathogenesis of myasthenia gravis. [PDF]

open access: yesJ Neurovirol
Dolci M   +11 more
europepmc   +1 more source

Myasthenia Gravis (abstract)

open access: yes, 2017
Myasthenia gravis is a disorder of neuromuscular transmission resulting from binding of autoantibodies to various components of the neuromuscular junction.
Matthew J. Thurtell
core  

Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod. [PDF]

open access: yesJ Neurol Neurosurg Psychiatry
Khani-Habibabadi F   +10 more
europepmc   +1 more source

Risk Factors for Cutaneous Immune‐Related Adverse Events in the Japanese Population: A Retrospective Single‐Center Cohort Study

open access: yesThe Journal of Dermatology, Volume 53, Issue 9, Page 1245-1260, September 2026.
ABSTRACT Immune checkpoint inhibitor (ICI)‐driven alterations in the immune system can induce immune‐related adverse events (irAEs). Cutaneous irAEs are notable for being the most common and for their early onset; however, the risk factors underlying their development and severity remain unclear. In this study, we retrospectively analyzed 1224 Japanese
Tomoya Watanabe   +4 more
wiley   +1 more source

Conversion Rate Of Ocular Myasthenia Gravis To Generalized Myasthenia Gravis

open access: yes, 2013
Ocular myasthenia gravis (OMG) is a common presentation to the neuro-ophthalmology clinic. Previous studies have reported that generalized myasthenia gravis (GMG) develops in 50% or more of patients presenting with OMG, usually within 2 years.
Lina Nagia; Khawla Abusamra; Eric R. Eggenberger
core  

Effect of Medication Intake on Dental Implant‐Related Outcomes—A Scoping Review

open access: yesClinical Oral Implants Research, Volume 37, Issue 9, Page 1033-1056, September 2026.
ABSTRACT Objective The objective of this scoping review was to evaluate the effect of systemic medications on dental implant outcomes in medically compromised patients. Material and Methods Electronic and manual searches were conducted for this scoping review.
Alberto Monje   +4 more
wiley   +1 more source

Clinical Variability and Genotype‐Driven Outcomes in CHRND‐Related Congenital Myasthenic Syndrome

open access: yesEuropean Journal of Neurology, Volume 33, Issue 9, September 2026.
Clinical variability in CHRND‐related congenital myasthenic syndrome ranges from isolated ocular involvement to severe neonatal‐onset disease with respiratory insufficiency. In a multicenter cohort of nine patients, ocular symptoms represented the core phenotype, while disease severity was influenced by genotype and presumed residual acetylcholine ...
David Muhmann   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy